Alphatec (NASDAQ:ATEC) Sets New 12-Month Low on Analyst Downgrade

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) reached a new 52-week low during mid-day trading on Monday after Weiss Ratings downgraded the stock from a sell (d-) rating to a sell (e+) rating. The stock traded as low as $6.78 and last traded at $6.8350, with a volume of 735,037 shares changing hands. The stock had previously closed at $7.07.

A number of other research analysts have also weighed in on ATEC. Wall Street Zen lowered Alphatec from a “buy” rating to a “hold” rating in a research report on Sunday, October 11th. UBS Group cut Alphatec from a “buy” rating to a “neutral” rating and cut their target price for the stock from $15.00 to $8.50 in a research note on Wednesday, November 4th. BMO Capital Markets cut Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 target price on the stock. in a research note on Friday, October 30th. Stephens began coverage on Alphatec in a report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price target for the company. Finally, Canaccord Genuity Group lowered their price target on Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Alphatec currently has a consensus rating of “Moderate Buy” and an average target price of $15.37.

Check Out Our Latest Stock Analysis on Alphatec

Insider Activity

In related news, Director David Demski purchased 60,000 shares of the company’s stock in a transaction dated Friday, October 30th. The shares were purchased at an average price of $6.81 per share, with a total value of $408,600.00. Following the acquisition, the director directly owned 491,635 shares in the company, valued at $3,348,034.35. The trade was a 13.90% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Miles acquired 115,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were bought at an average cost of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the acquisition, the chief executive officer directly owned 5,893,551 shares of the company’s stock, valued at $51,922,184.31. The trade was a 1.99% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 13.48% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alphatec

A number of hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new stake in shares of Alphatec during the 3rd quarter valued at $24,355,000. Paradigm Capital Management Inc. NY bought a new position in Alphatec in the 2nd quarter worth $9,413,000. Bank of America Corp DE increased its stake in Alphatec by 26.9% in the 1st quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock worth $27,863,000 after buying an additional 543,059 shares in the last quarter. Aberdeen Group plc increased its stake in Alphatec by 44.1% in the 3rd quarter. Aberdeen Group plc now owns 1,712,328 shares of the medical technology company’s stock worth $17,671,000 after buying an additional 523,747 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Alphatec in the 2nd quarter worth $3,092,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Stock Down 3.6%

The stock has a fifty day simple moving average of $9.75 and a 200 day simple moving average of $10.17. The firm has a market capitalization of $1.06 billion, a P/E ratio of -12.39 and a beta of 0.88.

Alphatec (NASDAQ:ATEC – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The business had revenue of $221.17 million during the quarter, compared to the consensus estimate of $225.16 million. During the same period last year, the company earned $0.03 EPS. The business’s revenue was up 12.6% on a year-over-year basis. Research analysts anticipate that Alphatec Holdings, Inc. will post -0.40 earnings per share for the current fiscal year.

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company’s product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.

Featured Stories

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.